Transitioning From S1P Receptor Modulators to B Cell–Depleting Therapies in Multiple Sclerosis: Clinical, Radiographic, and Laboratory Data

BACKGROUND AND OBJECTIVES: Patients with multiple sclerosis (MS) transition from oral sphingosine-1-receptor (S1P) modulators to anti-CD20 therapies for several circumstances. Optimal timing of this transition is uncertain, given competing concerns of rebound disease activity and ensuring immune rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Rowles, William M., Hsu, Wan-Yu, McPolin, Kira, Li, Alyssa, Merrill, Steven, Guo, Chu-Yueh, Green, Ari J., Gelfand, Jeffrey Marc, Bove, Riley M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128034/
https://www.ncbi.nlm.nih.gov/pubmed/35581005
http://dx.doi.org/10.1212/NXI.0000000000001183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128034/
https://www.ncbi.nlm.nih.gov/pubmed/35581005
http://dx.doi.org/10.1212/NXI.0000000000001183

Ejemplares similares